Почетна › Карцином ендометријума › Орегон
Kliničke studije za Карцином ендометријума u državi Орегон
27 studija za Карцином ендометријума traži učesnike na lokacijama u državi Орегон.
Gradovi u državi Орегон
Zvanični tekst studije (na engleskom)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 12. 11. 2026. · NCT05112601Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- и још 3
Тражи се учесникФаза 2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 12. 11. 2026. · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Oncology Associates of Oregon, P.C. ( Site 8005), Eugene
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Providence Cancer Institute of Oregon, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06515613Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 6. 11. 2026. · NCT07198074cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст 40 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05366881Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
- NW Cancer Specs. P.C., Happy Valley
- USOR - NW Cancer Specs P.C., Portland
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 3. 11. 2026. · NCT07166094Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
- Northwest Cancer Specialists, P.C., Happy Valley
- Northwest Cancer Specialists, P.C., Portland
- Northwest Cancer Specialists, P.C., Tigard
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 30. 10. 2026. · NCT07578649A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06242470A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT04657068Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
- Providence Cancer Institute (Westside), Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Eugene
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 13. 10. 2026. · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Oregon Health and Science University, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 10. 2026. · NCT05919264Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
Тражи се учесникФаза 1/2
Узраст од 18 до 130 · Оба пола · Ажурирано 5. 10. 2026. · NCT05797168The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT07814248Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT05867251Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Eugene
- Research Site, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 29. 7. 2026. · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 23. 7. 2026. · NCT06974110Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 16. 7. 2026. · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT05768139Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Oncology Associates of Oregon, P.C., Eugene
- Northwest Cancer Specialists, P.C., Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 24. 12. 2025. · NCT06463028SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Oregon Health & Science University, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2025. · NCT05669430Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oncology Associates of Oregon, Eugene
- Northwest Cancer Specialists, Portland
Тражи се учесникФаза 2/3
Узраст 18 и старији · Жене · Ажурирано 2. 5. 2024. · NCT05797831Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.